CHI'S PHARMA WEEK - New Blood Test Detects Early-Stage Breast Cancer

Top News and Analysis for R&D and Executive Leaders

Week of 10.1.08

tbar.gif

Neil W Gibson of OSI Pharmaceuticals

Jeffrey Settleman, Harvard Medical School and MGH Cancer Center

David Bailey of Chemoventures

N Claude Cohen of Synergix

-View All Webcasts

Exclusive Feature Archive

Infinity and MedImmune Announce Deal to Develop Anti-Cancer Agents

Pressure BioSciences

Finding the Magic in Fixed Combinations

Novartis Plunges into Hepatitis C Market

Real-Time Trials,

Affibody Molecules for Imaging and Treatment of HER2-Positive Tumors,

Apoptosis Field Springs to Life

J&J's Peter Juhn on The Value Proposition

Integrity of Clinical Samples Crucial to Quest for New Biomarkers

Wyeth's Orest Hurko on How Biomarkers Will Help

Decoding the Genetics of Common Disease

How Pfizer Defines Biomarkers: Three Oncology Case Studies

PerkinElmer CSO Neil Cook on Agilix Acquisition

Last Week’s Top News Item

Pfizer's Pick for CEO Reflects Change in Climate

Sponsored Links:
Individual Health Insurance

Prescription Drug Addiction


		Personalized Medicine

New Blood Test Detects Early-Stage Breast Cancer

August 4, 2006--A new blood test to detect breast cancer at a very early stage is 200–1,000 times more sensitive than existing tests. The test could particularly benefit younger women, for whom current mammography scans are less effective. Pilot studies suggest the test could also be used to identify prostate cancer, ovarian cancer, and melanoma. Details are published in the Journal of Proteome Research (abstract is free). Also see news story published by Guardian Unlimited.

FEATURE:

Prolong Pharmaceuticals – PEGged For Success?
By Alissa Poh

TOct. 1, 2008 | In Britain, people often use the phrase “pegging away” to describe working hard at something.

Across the pond, in New Jersey, the folks at Prolong Pharmaceuticals are also pegging away, attaching polyethylene glycol (PEG) to a variety of protein-based drugs. Or, to use the proper term, “pegylating” these drugs to improve pharmacokinetics, extend circulation time and decrease toxicity, all of which make for enhanced therapeutic effects.